# clm_2FCCACC23EDE

subject: Regeneron Pharmaceuticals (/record/regeneron-pharmaceuticals.md)  
predicate: net_income  
value: 4,338,400,000 United States dollar  
valid_from: 2022-12-31  
valid_to: 2023-12-31  
published: 2023-02-06  
recorded: 2026-11-08  
confidence: 0.95  
status: superseded  
assertable: true  
superseded_by: clm_11400CA0B8A6  
last_updated: 2026-11-08  
cite: AsOf. "Regeneron Pharmaceuticals net income: 4,338,400,000 United States dollar", as of 2022-12-31 (until 2023-12-31). Claim clm_2FCCACC23EDE, https://asof.is/claim/clm_2FCCACC23EDE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000008/0001804220-23-000008-index.htm.  
checked: 2026-11-08 · parsed from the SEC filing  
parsed from: us-gaap:NetIncomeLoss in 10-K FY2022, filed 2023-02-06  

## Sources

- https://www.sec.gov/Archives/edgar/data/872589/000180422023000008/0001804220-23-000008-index.htm (primary, SEC EDGAR 10-K FY2022, published 2023-02-06)

## Supersedes

- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | net_income | 8,075,300,000 United States dollar | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_2FCCACC23EDE](/claim/clm_2FCCACC23EDE.md) | [clm_D26172E0F6F8](/claim/clm_D26172E0F6F8.md)

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.